Researchers at the National Institute of Standards and Technology (NIST) have published an interesting study that sheds light on the fate of a familiar pharmaceutical as it enters the waste stream. In work initially described last year, NIST chemists investigated probable chemical reactions involving acetaminophen when the drug is subjected to typical wastewater processing. Acetaminophen is the most widely used pain reliever in the United States, and a study of 139 streams by the U.S. Geological Survey found that it was one of the most frequently detected man-made chemicals.

The scientists found that the drug readily reacts in chlorine disinfection to form at least 11 new products, at least two of which are known to be toxic. The results, according to lead author Mary Bedner, demonstrate that environmental scientists need to be concerned about downstream reaction products as well as the original waste materials. "The issue is what you should be looking for in the environment," she says. "When you are looking for the effects of pharmaceuticals in the environment, you need to ask what they're going to turn into."

'"/>

Contact: Michael Baum
michael.baum@nist.gov
301-975-2763
National Institute of Standards and Technology (NIST)
23-Dec-2005

Page: 1
Related medicine news :

1. Studying brain activity could aid diagnosis of social phobia
2. UIC researchers to develop new drugs to fight bioterrorism
3. Statin drugs may delay progressive artery damage in children
4. Study finds HIV protease inhibitor drugs may adversely affect the scaffolding of the cell nucleus
5. Experts call for urgent research into anti-epileptic drugs given to children
6. UCLA researchers develop new nanomaterials to deliver anti-cancer drugs to cells
7. Antipsychotic drugs increase risk of death in older people with dementia
8. Antipsychotic drugs increase risk of death in older people with dementia
9. Gene variations point to why lung cancer drugs work better in Japanese vs. US patients
10. Panel offers guidelines on skin reactions to new class of cancer drugs
11. Blood-thinning drugs need closer monitoring